Flipping the Cell’s Cleanup Switch: New Study Reveals How Inflammatory Signaling Regulates TFEB

HOUSTON – (May 2026) – Researchers working with Texas Children’s Hospital’s Duncan Neurological Research Institute (Duncan NRI), Baylor College of Medicine, Washington University and colleagues have identified a key molecular mechanism that regulates the stability of TFEB, a master protein responsible for controlling the cell’s waste-clearing and recycling system. The findings, published in Nature Communications, may pave the way for new treatments targeting neurodegenerative and other diseases linked to impaired cellular clearance. 

TFEB plays a central role in maintaining cellular health by regulating lysosomal biogenesis and degradation pathways—processes that enable cells to break down and recycle damaged components. Dysregulation of these pathways has been strongly linked to conditions such as Parkinson’s disease, Alzheimer’s disease, and other disorders involving toxic protein buildup. 
Senior author Dr. Marco Sardiello, collaborator with the Andrea Ballabio Lab at the Duncan NRI and former Associate Professor with Baylor and his collaborates have found a new mechanism that regulates TFEB protein levels. 

A newly discovered regulatory pathway
The research team discovered that the IKK complex, an inflammation regulator, controls the stability of TFEB through a coordinated phosphorylation–ubiquitination cascade. In this process IKK phosphorylates TFEB at specific sites which creates a recognition signal for β-TrCP2, tagging the protein for degradation. This process regulates the amount of TFEB protein in the cell and consequently the activity of the lysosomal and autophagic pathways.

Enhancing cellular clearance
Importantly, the researchers showed that inhibiting IKK or otherwise disrupting this degradation pathway increases TFEB stability. With more TFEB protein in the cell, they observed increased expression of lysosomal genes and cellular degradation capacity. 
These findings demonstrate that TFEB activity and the ability of a cell to clear toxic and/or pathological aggregate proteins can be selectively enhanced by targeting this pathway. 

Implications for disease treatment
Defective cellular clearance is a classic hallmark of many neurodegenerative disorders and age-related diseases. By identifying a central mechanism controlling TFEB turnover, this research highlights a potential treatment strategy for neurodegenerative disease not only to improve clearance of toxic protein, but also to improve the health of neurons and slow disease progression. 

The findings also suggest that targeting the IKK–β-TrCP2 pathway could represent a new therapeutic approach for conditions driven by impaired lysosomal function.  With a specific molecular target, the potential for drug development is especially promising. 

This work was led by investigators at Texas Children’s Hospital and Baylor College of Medicine in collaboration with academic partners and was supported by the National Institutes of Health.